Anika Therapeutics (ANIK) Set to Announce Earnings on Friday

Anika Therapeutics (NASDAQ:ANIK – Get Free Report) is projected to release its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect the company to announce earnings of $0.42 per share and revenue of $29.44 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 6, 2026 at 8:30 AM ET.

Anika Therapeutics (NASDAQ:ANIK – Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $0.42 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.39. Anika Therapeutics had a negative net margin of 3.14% and a positive return on equity of 0.20%. The company had revenue of $32.61 million during the quarter, compared to analyst estimates of $29.21 million. On average, analysts expect Anika Therapeutics to post $0.14 EPS for the current fiscal year and $0.29 EPS for the next fiscal year.

Anika Therapeutics Trading Up 1.1%

Anika Therapeutics stock opened at $21.79 on Friday. The stock’s 50 day simple moving average is $20.67 and its two-hundred day simple moving average is $15.97. Anika Therapeutics has a 12 month low of $9.01 and a 12 month high of $22.88. The firm has a market cap of $291.55 million, a PE ratio of 1,077.50, a P/E/G ratio of 15.39 and a beta of 0.21.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on ANIK shares. B. Riley Financial assumed coverage on Anika Therapeutics in a report on Friday, September 18th. They set a “buy” rating and a $23.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Anika Therapeutics in a report on Monday, September 21st. Barrington Research set a $21.00 price objective on shares of Anika Therapeutics in a research report on Thursday, July 30th. Zacks Research downgraded shares of Anika Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 28th. Finally, Wall Street Zen raised Anika Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 1st. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $22.00.

View Our Latest Report on ANIK

Anika Therapeutics Company Profile

(Get Free Report)

Anika Therapeutics, Inc develops, manufactures and commercializes therapeutic products designed to support tissue protection, healing and repair. The company focuses primarily on orthopedics, with products based in part on hyaluronic acid, a naturally occurring substance found in connective tissue and joint fluid.

Anika’s orthopedic portfolio includes Monovisc and Orthovisc, viscosupplementation products used to help relieve pain associated with osteoarthritis of the knee, as well as Cingal, which combines hyaluronic acid with a corticosteroid.

See Also

Earnings History for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.